Enterobiotix raised £19 million (about $25.7 million) to fund phase IIb development of its microbiome-based therapy for IBS-C. The company’s lead program, EBX-102-02, targets irritable bowel syndrome with constipation. The financing underscores continued investor appetite for gut microbiome approaches that can be advanced through late-stage proof-of-concept. For Enterobiotix, the capital is explicitly earmarked to support the clinical work needed to validate efficacy and dose-response before potential partnering or larger-scale trials. With microbiome programs competing for demonstration-quality outcomes, this round also signals that investors are looking for clear endpoints and execution readiness rather than early discovery alone.